HiCisco (002653.SZ): IND applications for “HSK50042” and “HSK55879” innovative drugs accepted

Zhitong Finance App News, Hisilco (002653.SZ) issued an announcement. The company's subsidiary Shanghai Hisense Pharmaceutical Technology Co., Ltd. recently received the “Notice of Acceptance” issued by the State Drug Administration, involving products: “HSK50042” and “HSK55879.”

SK50042 is an oral, potent, highly selective small molecule inhibitor drug independently developed by the company. It is intended for the treatment of respiratory diseases. Preclinical studies have shown that HSK50042 can effectively improve the pathological symptoms of lung disease in model mice at lower doses. It has good efficacy, and also shows good tolerability and a large safety window. It is a drug with great potential for development. This application is another clinical trial application for HSK50042 tablets in the field of respiratory diseases. It is expected to provide an efficient and safe novel treatment option for patients with respiratory diseases.

HSK55879 tablets are oral small molecule agonist drugs independently developed by the company with independent intellectual property rights, intended for the treatment of metabolic diseases. Preclinical study data showed that HSK55879 showed remarkable pharmacodynamic activity in related animal models, had a clear mechanism of action, showed good tolerability at different doses, and also had a large safety window. Based on existing results, HSK55879 has clear development value and good transformation prospects, and is expected to provide an efficient and safe novel treatment option for clinical patients.